Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Operating Leases (2020 - 2025)

Dare Bioscience's Operating Leases history spans 6 years, with the latest figure at $559365.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 25.85% year-over-year to $559365.0; the TTM value through Dec 2025 reached $559365.0, down 25.85%, while the annual FY2025 figure was $559365.0, 25.85% down from the prior year.
  • Operating Leases reached $559365.0 in Q4 2025 per DARE's latest filing, up from $288566.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.5 million in Q2 2024 to a low of $23326.0 in Q2 2023.
  • Average Operating Leases over 5 years is $690132.2, with a median of $675191.5 recorded in 2021.
  • Peak YoY movement for Operating Leases: crashed 97.17% in 2023, then soared 6437.77% in 2024.
  • A 5-year view of Operating Leases shows it stood at $384000.0 in 2021, then crashed by 76.47% to $90346.0 in 2022, then soared by 935.73% to $935743.0 in 2023, then dropped by 19.38% to $754383.0 in 2024, then fell by 25.85% to $559365.0 in 2025.
  • Per Business Quant, the three most recent readings for DARE's Operating Leases are $559365.0 (Q4 2025), $288566.0 (Q3 2025), and $1.0 million (Q2 2025).